These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 29566829)

  • 1. Affordability of New Technologies: The Next Frontier.
    Towse A; Mauskopf JA
    Value Health; 2018 Mar; 21(3):249-251. PubMed ID: 29566829
    [No Abstract]   [Full Text] [Related]  

  • 2. Transparency of economic evaluations of health technologies.
    Rovira J
    Pharmacoeconomics; 2008; 26(3):181-3. PubMed ID: 18282013
    [No Abstract]   [Full Text] [Related]  

  • 3. Improving the usefulness of budget impact analyses: a U.S. payer perspective.
    Watkins JB; Danielson D
    Value Health; 2014; 17(1):3-4. PubMed ID: 24438711
    [No Abstract]   [Full Text] [Related]  

  • 4. Cost effective but unaffordable: an emerging challenge for health systems.
    Charlton V; Littlejohns P; Kieslich K; Mitchell P; Rumbold B; Weale A; Wilson J; Rid A
    BMJ; 2017 Mar; 356():j1402. PubMed ID: 28330879
    [No Abstract]   [Full Text] [Related]  

  • 5. Largest biotechnology companies.
    Mod Healthc; 2013 Sep; 43(39):34. PubMed ID: 24199305
    [No Abstract]   [Full Text] [Related]  

  • 6. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices--budget impact analysis.
    Mauskopf JA; Sullivan SD; Annemans L; Caro J; Mullins CD; Nuijten M; Orlewska E; Watkins J; Trueman P
    Value Health; 2007; 10(5):336-47. PubMed ID: 17888098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is rate of return pricing a useful approach when value-based pricing is not appropriate?
    Drummond M; Towse A
    Eur J Health Econ; 2019 Sep; 20(7):945-948. PubMed ID: 30771033
    [No Abstract]   [Full Text] [Related]  

  • 8. Value-Based Pricing in Latin America: How Far Away Are We?
    Mejía A; Gilardino R; Kristensen FB; Garrison LP;
    Value Health Reg Issues; 2018 Dec; 17():219-223. PubMed ID: 30528780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Striking a balance on new technology. Cost-effectiveness analysis can help sort out emerging health care technologies, but what are the consequences for continued medical innovation?
    Philipson TJ; Jena AB
    AHIP Cover; 2006; 47(5):29, 31, 33. PubMed ID: 17007325
    [No Abstract]   [Full Text] [Related]  

  • 11. Budget impact analysis.
    Silva MT; Silva END; Pereira MG
    Epidemiol Serv Saude; 2017; 26(2):421-424. PubMed ID: 28492784
    [No Abstract]   [Full Text] [Related]  

  • 12. A small step for science, a big one for commerce.
    Birkett L
    Stud Health Technol Inform; 2005; 117():101-3. PubMed ID: 16282658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Irrelevance of explicit cost-effectiveness thresholds when coverage decisions can be reversed.
    Basu A
    Expert Rev Pharmacoecon Outcomes Res; 2013 Apr; 13(2):163-5. PubMed ID: 23570425
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of technology on health care cost and policy development.
    Wallner PE; Konski A
    Semin Radiat Oncol; 2008 Jul; 18(3):194-200. PubMed ID: 18513629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget impact analyses get some respect.
    Neumann PJ
    Value Health; 2007; 10(5):324-5. PubMed ID: 17888096
    [No Abstract]   [Full Text] [Related]  

  • 16. Modeling for health care and other policy decisions: uses, roles, and validity.
    Langley PC
    Value Health; 2002; 5(1):60-1; author reply 61-2. PubMed ID: 11873386
    [No Abstract]   [Full Text] [Related]  

  • 17. A changing paradigm in the study and adoption of emerging health care technologies: coverage with evidence development.
    Wallner PE; Konski A
    J Am Coll Radiol; 2008 Nov; 5(11):1125-9. PubMed ID: 18954812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transparency in economic evaluations.
    Hill S
    Pharmacoeconomics; 2005; 23(10):967-9. PubMed ID: 16235971
    [No Abstract]   [Full Text] [Related]  

  • 19. Fundraising initiatives and vendor solicitation: avoiding kickback implications.
    Gordon L
    Health Care Law Mon; 2007 Mar; ():3-6. PubMed ID: 17460840
    [No Abstract]   [Full Text] [Related]  

  • 20. A change in spending habits. Technology, construction budgets take hits as systems refocus priorities.
    Evans M
    Mod Healthc; 2013 Feb; 43(6):32-3. PubMed ID: 23487908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.